Identification of Specific Molecular Signatures in Pediatric, Adolescent, and Young Adult Rhabdom… (NCT06924463) | Clinical Trial Compass
RecruitingNot Applicable
Identification of Specific Molecular Signatures in Pediatric, Adolescent, and Young Adult Rhabdomyosarcoma Through Spatial Proteome Analysis Using Mass Spectrometry
France20 participantsStarted 2025-03-13
Plain-language summary
This non-interventional study aims to develop spatial proteomics for analyzing small FFPE tumor samples in rhabdomyosarcoma. It will identify molecular signatures linked to tumor regions, subtypes, survival, and treatment resistance, using pre-existing samples and data.
Who can participate
Age range
0 Years – 25 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age between 0 and 25 years at the time of initial diagnosis
* Diagnosis of rhabdomyosarcoma confirmed histologically
* Care at the Oscar Lambret Center between January 2005 and November 2024
* No objection to the re-use of data and biological samples collected as part of care for research activities.
Exclusion Criteria:
* Unavailability of biological sample in FFPE from biopsy and/or surgical specimen for diagnosis at Centre Oscar Lambret;
* Patient under guardianship or trusteeship.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial focuses on analyzing tumor tissue samples to find molecular signatures in rhabdomyosarcoma — does my child's tumor sample meet the requirements for this kind of spatial proteomics research, and would participation involve collecting any additional tissue beyond what's already being removed for diagnosis or treatment?
2Since this study is listed as Phase NA, it appears to be a research or observational study rather than a treatment trial — can you help me understand what my child would actually be asked to do, and whether participating would have any effect on their standard treatment plan?
3The study is looking at molecular patterns in rhabdomyosarcoma tumors specifically in pediatric, adolescent, and young adult patients — could the findings from this research potentially inform my child's own treatment decisions down the line, or is this purely for future scientific understanding?
4Since this is a tissue and molecular profiling study rather than a drug trial, what are the potential risks or burdens involved in participating — for example, are there privacy considerations around having my child's tumor genetic data analyzed and stored?
5Are there other treatment trials or studies currently available for rhabdomyosarcoma that we should be considering alongside or instead of this one, given that this study doesn't appear to offer a new therapy?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.